GT Biopharma Statistics
Want to see GTBP full AI Analyst Report?
GT Biopharma (GTBP) Stock Statistics & Valuation Metrics
Total Valuation
GT Biopharma has a market cap or net worth of $8.16M. The enterprise value is $13.96M.
- Market Cap
- $8.16M
- Enterprise Value
- $13.96M
Share Statistics
GT Biopharma has 2,061,052 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 2,061,052
- Owned by Insiders
- ―
- Owned by Institutions
- 0.74%
Financial Efficiency
GT Biopharma’s return on equity (ROE) is -4.90 and return on invested capital (ROIC) is -214.65%.
- Return on Equity (ROE)
- -4.90
- Return on Assets (ROA)
- -3.50
- Return on Invested Capital (ROIC)
- -214.65%
- Return on Capital Employed (ROCE)
- -2.15
- Revenue Per Employee
- 0
- Profits Per Employee
- -28.35M
- Employee Count
- 1
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of GT Biopharma is -0.04. GT Biopharma’s PEG ratio is 0.00.
- PE Ratio
- -0.04
- PS Ratio
- 0.00
- PB Ratio
- 1.72
- Price to FCF
- -0.35
- Price to Operating Cash Flow
- -0.43
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, GT Biopharma had revenue of 0 and earned -28.35M in profits. Earnings per share was -156.25.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -12.42M
- Pretax Income
- -28.35M
- Net Income
- -28.35M
- EBITDA
- -28.23M
- Earnings Per Share (EPS)
- -156.25
Cash Flow
In the last 12 months, operating cash flow was -14.43M and capital expenditures 0, giving a free cash flow of -14.43M billion.
- Operating Cash Flow
- -14.43M
- Free Cash Flow
- -14.43M
- Free Cash Flow per Share
- -9.29
Dividends & Yields
GT Biopharma pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -272.78%
- Earnings Yield
- -339.41%
Stock Price Statistics
- Beta
- 0.73
- 52-Week Price Change
- -75.92%
- 50-Day Moving Average
- 6.47
- 200-Day Moving Average
- 9.21
- Relative Strength Index (RSI)
- 31.68
- Average Volume (3m)
- 71.89K
Important Dates
GT Biopharma upcoming earnings date is Mar 31, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 11, 2026
- Next Earnings Date
- Mar 31, 2027
- Ex-Dividend Date
- ―
Financial Position
GT Biopharma as a current ratio of 3.50, with Debt / Equity ratio of 0.00%
- Current Ratio
- 3.50
- Quick Ratio
- 3.50
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.24
- Interest Coverage Ratio
- -97.81
Taxes
In the past 12 months, GT Biopharma has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
GT Biopharma EV to EBITDA ratio is -0.02, with an EV/FCF ratio of -0.02.
- EV to Sales
- 0.00
- EV to EBITDA
- -0.02
- EV to Free Cash Flow
- -0.02
- EV to Operating Cash Flow
- -0.02
Balance Sheet
GT Biopharma has $4.96M in cash and marketable securities with $0.00 in debt, giving a net cash position of $4.96M billion.
- Cash & Marketable Securities
- $4.96M
- Total Debt
- $0.00
- Net Cash
- $4.96M
- Net Cash Per Share
- $2.41
- Tangible Book Value Per Share
- $2.30
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for GT Biopharma is $3.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $3.00
- Price Target Upside
- 24.24% Downside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 1
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 75.09%
Scores
- Smart Score
- ―
- AI Score
- 42
